Literature DB >> 11736871

The glucuronidation of mycophenolic acid by human liver, kidney and jejunum microsomes.

K Bowalgaha1, J O Miners.   

Abstract

AIMS: To estimate the relative contribution of liver, kidney and jejunum to MPA elimination via glucuronidation from in vitro kinetic data.
METHODS: The kinetics of MPA glucuronidation by human liver, kidney and jejunum microsomes were characterized. Mycophenolic acid glucuronide (MPAG) concentrations in microsomal incubations were determined using a specific h.p.l.c. procedure. Non-specific microsomal binding of MPA was excluded using an equilibrium dialysis approach.
RESULTS: Microsomes from all three tissues catalysed the conversion of MPA to MPAG. Mean microsomal intrinsic clearances for MPAG formation by liver, kidney and jejunum microsomes were 46.6, 73.5 and 24.5 microl (min mg)(-1), respectively. When extrapolated to the whole organ, however, hepatic intrinsic clearance was 21- and 38-fold higher than the respective intrinsic clearances for kidney and small intestine.
CONCLUSIONS: The data suggest that the liver is the organ primarily responsible for the systemic clearance of MPA, with little contribution from the kidney, and that the small intestine would be expected to contribute to first-pass extraction to a minor extent only.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11736871      PMCID: PMC2014615          DOI: 10.1046/j.0306-5251.2001.01487.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  13 in total

1.  The human UDP glucuronosyltransferase, UGT1A10, glucuronidates mycophenolic acid.

Authors:  B Mojarrabi; P I Mackenzie
Journal:  Biochem Biophys Res Commun       Date:  1997-09-29       Impact factor: 3.575

2.  Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration.

Authors:  R Bullingham; S Monroe; A Nicholls; M Hale
Journal:  J Clin Pharmacol       Date:  1996-04       Impact factor: 3.126

Review 3.  Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance.

Authors:  J B Houston
Journal:  Biochem Pharmacol       Date:  1994-04-29       Impact factor: 5.858

4.  Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophenolic acid glucuronidation.

Authors:  K Zucker; A Tsaroucha; L Olson; V Esquenazi; A Tzakis; J Miller
Journal:  Ther Drug Monit       Date:  1999-02       Impact factor: 3.681

5.  Nonspecific binding of drugs to human liver microsomes.

Authors:  J A McLure; J O Miners; D J Birkett
Journal:  Br J Clin Pharmacol       Date:  2000-05       Impact factor: 4.335

6.  Glucuronide and glucoside conjugation of mycophenolic acid by human liver, kidney and intestinal microsomes.

Authors:  M Shipkova; C P Strassburg; F Braun; F Streit; H J Gröne; V W Armstrong; R H Tukey; M Oellerich; E Wieland
Journal:  Br J Pharmacol       Date:  2001-03       Impact factor: 8.739

Review 7.  Genetic multiplicity of the human UDP-glucuronosyltransferases and regulation in the gastrointestinal tract.

Authors:  R H Tukey; C P Strassburg
Journal:  Mol Pharmacol       Date:  2001-03       Impact factor: 4.436

8.  UDP glucuronosyltransferase and mixed function oxidase activity in microsomes prepared by differential centrifugation and calcium aggregation.

Authors:  A Aitio; H Vainio
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1976

9.  Characterisation of theophylline metabolism in human liver microsomes.

Authors:  R A Robson; A P Matthews; J O Miners; M E McManus; U A Meyer; P M Hall; D J Birkett
Journal:  Br J Clin Pharmacol       Date:  1987-09       Impact factor: 4.335

Review 10.  Clinical pharmacokinetics of mycophenolate mofetil.

Authors:  R E Bullingham; A J Nicholls; B R Kamm
Journal:  Clin Pharmacokinet       Date:  1998-06       Impact factor: 6.447

View more
  23 in total

1.  Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.

Authors:  Katherine L Gill; J Brian Houston; Aleksandra Galetin
Journal:  Drug Metab Dispos       Date:  2012-01-24       Impact factor: 3.922

Review 2.  Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients.

Authors:  Christine E Staatz; Susan E Tett
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 3.  A perspective on efflux transport proteins in the liver.

Authors:  K Köck; K L R Brouwer
Journal:  Clin Pharmacol Ther       Date:  2012-09-05       Impact factor: 6.875

4.  S-Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen.

Authors:  Kushari Bowalgaha; David J Elliot; Peter I Mackenzie; Kathleen M Knights; Stellan Swedmark; John O Miners
Journal:  Br J Clin Pharmacol       Date:  2005-10       Impact factor: 4.335

5.  Comparative metabolism of mycophenolic acid by glucuronic acid and glucose conjugation in human, dog, and cat liver microsomes.

Authors:  J E Slovak; K Mealey; M H Court
Journal:  J Vet Pharmacol Ther       Date:  2016-06-15       Impact factor: 1.786

6.  Diabetes mellitus reduces activity of human UDP-glucuronosyltransferase 2B7 in liver and kidney leading to decreased formation of mycophenolic acid acyl-glucuronide metabolite.

Authors:  Miroslav Dostalek; Michael H Court; Suwagmani Hazarika; Fatemeh Akhlaghi
Journal:  Drug Metab Dispos       Date:  2010-12-01       Impact factor: 3.922

7.  Pharmacogenetic effect of the UGT polymorphisms on mycophenolate is modified by calcineurin inhibitors.

Authors:  L'aurelle A Johnson; William S Oetting; Saonli Basu; Susie Prausa; Arthur Matas; Pamala A Jacobson
Journal:  Eur J Clin Pharmacol       Date:  2008-06-21       Impact factor: 2.953

8.  Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients.

Authors:  Brenda C M de Winter; Teun van Gelder; Ferdi Sombogaard; Leslie M Shaw; Reinier M van Hest; Ron A A Mathot
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-11-11       Impact factor: 2.745

9.  Relative importance of intestinal and hepatic glucuronidation-impact on the prediction of drug clearance.

Authors:  Helen E Cubitt; J Brian Houston; Aleksandra Galetin
Journal:  Pharm Res       Date:  2009-01-31       Impact factor: 4.200

10.  Mycophenolate pharmacokinetics and association with response to acute graft-versus-host disease treatment from the Blood and Marrow Transplant Clinical Trials Network.

Authors:  Pamala A Jacobson; Jiayin Huang; Juan Wu; Miae Kim; Brent Logan; Amin Alousi; Michael Grimley; Javier Bolaños-Meade; Vincent Ho; John E Levine; Daniel Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2010-03       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.